Skip to main content

Table 1 Clinical characteristics and treatment of the study participants

From: Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy

Variable

Value

No. of participants

24

Demographics a

 Age (years)

47.2 ± 11.1

 Height (cm)

161.0 ± 4.3

 Weight (kg)

61.9 ± 9.1

 Body surface area (m2)

1.62 ± 0.13

Cardiovascular risk factors b

 Obesity (body mass index > 30 kg/m2)

3 (12.5)

 Age 65–79 years

2 (8.3)

 Arterial hypertension

1 (5.0)

 Diabetes

0 (0.0)

 Prior cardiovascular disease

0 (0.0)

HFA-ICOS baseline cardiovascular toxicity risk stratification b

 Moderate risk (with a total of 2 points)

2 (8.3)

 Low risk

22 (91.7)

 No risk factors

19 (79.2)

 One moderate risk with a total of 1 point

3 (12.5)

 Cardiac medication

0 (0.0)

 Left-/right-sided breast cancer b

15 (62.5)/9 (37.5)

Anti-HER2 therapy b

 Trastuzumab

8 (33.3)

 Trastuzumab and pertuzumab

16 (66.7)

 Interval time between baseline and follow-up MRI (days)

107.5 ± 19.7

  1. a Data are given as mean ± standard deviation. b Data in parentheses are percentages. HER2 Human epidermal growth factor receptor 2; HFA-ICOS Heart Failure Association-International Cardio-Oncology Society, MRI Magnetic resonance imaging